<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Terlipressin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Terlipressin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Terlipressin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="135373" href="/d/html/135373.html" rel="external">see "Terlipressin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F57211250"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Serious or fatal respiratory failure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Terlipressin may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (eg, SpO2) before initiating terlipressin<b>. </b></p>
<p style="text-indent:-2em;margin-left:2em;">Do not initiate terlipressin in patients experiencing hypoxia (eg, SpO2 &lt;90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue terlipressin if SpO2 decreases below 90%.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57522483"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Terlivaz</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F22334619"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiuretic Hormone Analog;</li>
<li>
                        Hormone, Posterior Pituitary</li></ul></div>
<div class="block doa drugH1Div" id="F57280661"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="741f2f95-4bbd-4f0b-a86f-9280d55d9dc0">Hepatorenal syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatorenal syndrome: </b>
<b>Note: </b>Patients with SCr &gt;5 mg/dL at the time of treatment initiation are unlikely to experience benefit. Concurrent use of albumin was utilized in clinical trials.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Initial: 0.85 mg every 6 hours for 3 days. Beginning on day 4, adjust dose based on SCr as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">If SCr has decreased by ≥30% from baseline: Continue 0.85 mg every 6 hours until 24 hours after patient achieves 2 consecutive creatinine values (at least 2 hours apart) of ≤1.5 mg/dL or for a maximum of 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">If SCr has decreased by &lt;30% from baseline: Increase to 1.7 mg every 6 hours; continue until 24 hours after patient achieves 2 consecutive creatinine values (at least 2 hours apart) of ≤1.5 mg/dL or for a maximum of 14 days.</p>
<p style="text-indent:-2em;margin-left:6em;">If SCr ≥ baseline: Discontinue terlipressin.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F57280663"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to severe impairment: <b>Note:</b> Patients with SCr &gt;5 mg/dL at the time of treatment initiation are unlikely to experience benefit.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: No dosage adjustment necessary (&lt;1% eliminated in the urine); subsequent dose adjustments should be determined based on SCr response beginning on day 4 of therapy (see adult dosing for specific recommendations).</p></div>
<div class="block doha drugH1Div" id="F57280664"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild to severe impairment: No dosage adjustment necessary.</p></div>
<div class="block dot drugH1Div" id="F57280665"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Fluid overload: In conjunction with reducing or discontinuing the administration of albumin and/or other fluids and judicious use of diuretics, temporarily interrupt, reduce, or discontinue terlipressin until patient volume status improves.</p>
<p style="text-indent:-2em;margin-left:2em;">Ischemic signs or symptoms: Discontinue terlipressin in patients with signs of ischemia (eg, angina, ECG changes, abdominal pain, peripheral cyanosis, or extremity pain).</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory effects: Discontinue terlipressin in patients who develop hypoxia or increase in respiratory symptoms.</p></div>
<div class="block doe drugH1Div" id="F57280662"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F57438837"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyponatremia</b> has been reported with terlipressin administration; can be severe, inducing neurological manifestations (eg, change in mental status, cognitive deficits, delirium, encephalopathy, personality changes, seizures) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573870','lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573870','lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983'])">Ref</a></span>). Onset of hyponatremia may be preceded by a substantial fluid retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26995205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26995205'])">Ref</a></span>). Serum sodium levels typically recover rapidly after discontinuation of terlipressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; likely due to stimulation of V<sub>1</sub> receptors of the smooth muscles in the splanchnic area (improving circulatory volume and urine volume) and V<sub>2</sub> receptors in the renal collecting ducts (resulting in antidiuretic activity by reducing solute-free water clearance and increasing water reabsorption causing a dilution hyponatremia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26573870','lexi-content-ref-31421059','lexi-content-ref-26995205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26573870','lexi-content-ref-31421059','lexi-content-ref-26995205'])">Ref</a></span>). Less likely to occur in decompensated hepatic function and/or high model for end-stage liver disease (MELD) score secondary to endogenous vasopressin saturation of the V<sub>2</sub> receptors and preexisting hyponatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; onset has been reported within 2 to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421059','lexi-content-ref-26995205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421059','lexi-content-ref-26995205'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased MELD scores, preserved hepatic function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421059','lexi-content-ref-26995205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421059','lexi-content-ref-26995205'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline serum sodium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31421059','lexi-content-ref-26995205','lexi-content-ref-23948983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26995205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26995205'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ischemic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe and life-threatening ischemic events, including cardiac ischemia (eg, <b>acute myocardial infarction</b>), cerebrovascular ischemia, <b>mesenteric</b>
<b>ischemia </b>(eg, <b>intestinal necrosis</b>), and <b>peripheral ischemia</b> (eg, <b>peripheral cyanosis, skin necrosis, peripheral gangrene</b>, <b>skin discoloration</b>) have been reported with terlipressin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33267600','lexi-content-ref-24855284','lexi-content-ref-30600312','lexi-content-ref-20466263','lexi-content-ref-24459647','lexi-content-ref-31948983','lexi-content-ref-23837143','lexi-content-ref-15696791','lexi-content-ref-23907969','lexi-content-ref-20818227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33267600','lexi-content-ref-24855284','lexi-content-ref-30600312','lexi-content-ref-20466263','lexi-content-ref-24459647','lexi-content-ref-31948983','lexi-content-ref-23837143','lexi-content-ref-15696791','lexi-content-ref-23907969','lexi-content-ref-20818227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; activated V receptors (especially V<sub>1</sub> receptors) produce vasoconstrictive effects on cardiac, splanchnic, and peripheral circulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24855284','lexi-content-ref-30600312','lexi-content-ref-23837143','lexi-content-ref-23907969','lexi-content-ref-20818227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24855284','lexi-content-ref-30600312','lexi-content-ref-23837143','lexi-content-ref-23907969','lexi-content-ref-20818227'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; can occur within 1 to 11 days of terlipressin administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31948983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31948983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of severe cardiovascular, cerebrovascular, and/or ischemic disease</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypovolemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant pressor drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Continuous infusion administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33267600','lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33267600','lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Venous insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33267600','lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33267600','lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Spontaneous bacterial peritonitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33267600','lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33267600','lexi-content-ref-23837143'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Non-alcoholic fatty liver disease-related cirrhosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23837143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23837143'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Respiratory failure</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Terlipressin may cause severe or fatal <b>respiratory failure</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35006099','lexi-content-ref-12492732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35006099','lexi-content-ref-12492732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume overload</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>• </b>Acute-on-chronic liver failure grade 3</p>
<p style="text-indent:-2em;margin-left:6em;">• Pretreatment respiratory compromise (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35006099','lexi-content-ref-35721838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35006099','lexi-content-ref-35721838'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57215482"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (20%), diarrhea (13%), nausea (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (13%), respiratory failure (16%; severe: 14%)<span class="lexi-table-link-container"> (<a aria-label="Respiratory Failure table link" class="lexi-table-link" data-table-id="lexi-content-respiratory-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-respiratory-failure')">table 1</a>)</span><span class="table-link" style="display:none;">Respiratory Failure</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Respiratory Failure" frame="border" id="lexi-content-respiratory-failure" rules="all">
<caption style="text-align:center;">
<b>Terlipressin: Adverse Reaction: Respiratory Failure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Terlipressin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Terlipressin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Average daily dose of 3.1 mg (range 0.8 to 5.8 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Severe: 14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Average daily dose of 3.1 mg (range 0.8 to 5.8 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (5%), ischemia (5%; including cyanosis, mesenteric ischemia, peripheral cyanosis [Chiang 2019], peripheral gangrene [Lee 2013], peripheral ischemia [Elzouki 2010], skin discoloration, and skin necrosis [Nistal 2021])<span class="lexi-table-link-container"> (<a aria-label="Ischemia table link" class="lexi-table-link" data-table-id="lexi-content-ischemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ischemia')">table 2</a>)</span><span class="table-link" style="display:none;">Ischemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ischemia" frame="border" id="lexi-content-ischemia" rules="all">
<caption style="text-align:center;">
<b>Terlipressin: Adverse Reaction: Ischemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Terlipressin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Terlipressin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Average daily dose of 3.1 mg (range 0.8 to 5.8 mg)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">200</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">99</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as ischemia-related events including skin discoloration, cyanosis, ischemia, and intestinal ischemia.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypervolemia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Carmo 2016, Lee 2004), cardiogenic shock (Elzouki 2010), left ventricular dysfunction (including left ventricular failure, left ventricular posterior wall hypokinesia, and takotsubo cardiomyopathy) (DiMicoli 2011, Ghatak 2014), prolonged QT interval on ECG (including torsades de pointes) (Sidhu 2013), supraventricular tachycardia (Elzouki 2010), ventricular dysfunction (Elzouki 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Gangrene of skin and/or subcutaneous tissues (Elzouki 2010, Lee 2013), skin necrosis (Kulkarni 2020, Nistal 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyponatremia (Meng 2019, Sima 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Intestinal necrosis (Kim 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Zimmer 2010)</p></div>
<div class="block coi drugH1Div" id="F22334669"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Patients with ongoing coronary, peripheral or mesenteric ischemia; hypoxia or worsening respiratory symptoms.</p></div>
<div class="block war drugH1Div" id="F57280648"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute-on-chronic liver failure: Avoid use in patients with acute-on-chronic liver failure grade 3, as these patients are at significantly increased risk of respiratory failure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Avoid use in patients with a history of severe cardiovascular conditions, cerebrovascular disease, and ischemic disease, as terlipressin may cause ischemic events.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Liver transplant candidates: Terlipressin-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed. For patients with high prioritization for liver transplantation (eg, MELD ≥35), evaluate the benefits versus the risks of terlipressin therapy.</p></div>
<div class="block foc drugH1Div" id="F57522484"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Terlivaz: 0.85 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F57494986"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57509868"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Terlivaz Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.85 mg (per each): $1,140.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57280666"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer as an IV bolus slowly over 2 minutes through a peripheral or central line. Flush the line after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate phentolamine (or alternative) antidote (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Nitroglycerin topical 2% ointment (based on mechanism of extravasation injury): Apply a 1-inch strip to the site of ischemia to cover the affected area; may repeat every 8 hours as necessary (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">Terbutaline:</p>
<p style="text-indent:-2em;margin-left:8em;">Large extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS; may repeat dose after 15 minutes (Stefanos 2023).</p>
<p style="text-indent:-2em;margin-left:8em;">Small extravasations: <b>SUBQ: </b>Infiltrate affected extravasation area with terbutaline 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (Stefanos 2023).</p></div>
<div class="block use drugH1Div" id="F247806"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatorenal syndrome:</b> To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The American Association for the Study of Liver Diseases guidance for the diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome, the American College of Gastroenterology clinical guidelines for acute-on-chronic liver failure and the European Association for the Study of the Liver guidelines for the management of decompensated cirrhosis recommend terlipressin (in combination with albumin) as a first-line treatment option (AASLD [Biggins 2021]; ACG [Bajaj 2022]; EASL [Angeli 2018]).</p></div>
<div class="block cyt drugH1Div" id="F57229894"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57229891"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F57280646"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Terlipressin causes uterine contractions and endometrial ischemia. Based on the mechanism of action and data from animal reproduction studies, in utero exposure to terlipressin may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F57280647"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if terlipressin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57280668"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum creatinine (baseline and periodically during therapy); oxygen saturation (baseline and during therapy via continuous pulse oximetry and clinical assessments); Acute-on-Chronic Liver Failure Grade and volume status (baseline and periodically during treatment); signs and symptoms of fluid overload or ischemia.</p></div>
<div class="block pha drugH1Div" id="F57280652"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Terlipressin, a synthetic vasopressin analogue with twice the selectivity for vasopressin V<sub>1</sub> receptors versus V<sub>2</sub> receptors, has intrinsic activity; however, a majority of the activity results from conversion to lysine-vasopressin via slow enzymatic cleavage, producing an extended duration of systemic vasoconstriction. Reduces portal pressure and blood flow into portal vessels, increasing effective arterial blood volume and mean arterial pressure, thereby increasing blood flow to the kidneys.</p></div>
<div class="block phk drugH1Div" id="F57280653"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: BP and mean arterial pressure increased and heart rate decreased within 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: ≥6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Terlipressin: 6.3 L; lysine-vasopressin: 1,370 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Terlipressin is cleaved to lysine-vasopressin (active metabolite) by various tissue peptidases, which is then metabolized by tissue peptidase-mediated routes.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: Terlipressin: 0.9 hours; lysine-vasopressin: 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Maximal change in BP and heart rate:1.2 to 2 hours post dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (terlipressin: &lt;1%; lysine-vasopressin: &lt;0.1%).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23666684"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Glycylpressin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Glycylpressin | Haemopressintorrex pharma | Terlipressinacetat ever pharma</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipressin ever pharma</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Variquel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Remestyp</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Tergly</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Glycylpressin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Han wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin | Pleuxed</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipresin acetat ever pharma</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Glycylpressin | Haemopressin | Terlipressin acetate ever pharma | Terlipressin Inresa | Terlipressin sun | Variquel</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipresina acetate ever pharma | Terlipresina ges | Terlipresina sun | Variquel</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Stemflova | Terlipressin sun</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Glypressine | Haemopressin | Terlipressine altan | Variquel</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipressin EVER Pharma | Variquel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Terlipin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">T pressin | Telipsa | Terlibax | Terloc | Terpres | Tresil | Tripez</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glipressina | Stemflova | Terlipressina acetato ever pharma | Terlipressina Dr. Reddy's | Terlipressina sun | Variquel</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Novapressin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin | Pressin | Remestyp | Terepin | Teripin | Teripin s</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bogarexi | Glypressin | Glyverase | Suatek | Terlipresina | Zuphater</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Novapressin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin | Terlipressine | Variquel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Stemflova</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Novapressin | Terliget | Terlip</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Remestyp | Terlipressin acetas ever pharma</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Glypressine | Terlipressina ever pharma | Variquel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acetat de terlipresina ever pharma | Glypressin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipressin sun | Variquel</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Terlipresin ever pharma</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Glypressine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Glypressin | Haemopressin | Terlissin | Variquel</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Everpressin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Glypressin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25638527">
<a name="25638527"></a>Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>J Hepatol</i>. 2015;62(4):968-974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/25638527/pubmed" id="25638527" target="_blank">25638527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35006099">
<a name="35006099"></a>Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. <i>Am J Gastroenterol</i>. 2022;117(2):225-252. doi:10.14309/ajg.0000000000001595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/35006099/pubmed" id="35006099" target="_blank">35006099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35721838">
<a name="35721838"></a>Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. <i>Therap Adv Gastroenterol</i>. 2022;15:17562848221102679. doi:10.1177/17562848221102679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/35721838/pubmed" id="35721838" target="_blank">35721838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33267600">
<a name="33267600"></a>Busta Nistal MR, Mora Cuadrado N, Fernández Salazar L. Ischemic skin necrosis secondary to the use of terlipressin. <i>Rev Esp Enferm Dig</i>. 2021;113(8):617. doi:10.17235/reed.2020.7467/2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/33267600/pubmed" id="33267600" target="_blank">33267600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24855284">
<a name="24855284"></a>Carmo LS, Baima DC, Blefari V, Zonta V, Troncon LE, Rossi MA. Involvement of the microvasculature in the pathogenesis of terlipressin-related myocardial infarction. <i>Eur Heart J Acute Cardiovasc Care</i>. 2016;5(8):505-511. doi:10.1177/2048872614534921<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/24855284/pubmed" id="24855284" target="_blank">24855284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30600312">
<a name="30600312"></a>Chiang CW, Lin YJ, Huang YB. Terlipressin-induced peripheral cyanosis in a patient with liver cirrhosis and hepatorenal syndrome. <i>Am J Case Rep</i>. 2019;20:5-9. doi:10.12659/AJCR.913150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/30600312/pubmed" id="30600312" target="_blank">30600312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20466263">
<a name="20466263"></a>Elzouki AN, El-Menyar A, Ahmed E, Elbadri ME, Imam YZ, Gurbanna BA. Terlipressin-induced severe left and right ventricular dysfunction in patient presented with upper gastrointestinal bleeding: case report and literature review. <i>Am J Emerg Med</i>. 2010;28(4):540.e1-6. doi:10.1016/j.ajem.2009.08.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/20466263/pubmed" id="20466263" target="_blank">20466263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26573870">
<a name="26573870"></a>Huang Y, Wang M, Wang J. Hyponatraemia induced by terlipressin: a case report and literature review. <i>J Clin Pharm Ther</i>. 2015;40(6):626-8. doi:10.1111/jcpt.12335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/26573870/pubmed" id="26573870" target="_blank">26573870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12492732">
<a name="12492732"></a>Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. <i>Aliment Pharmacol Ther</i>. 2003;17(1):53-64. doi:10.1046/j.1365-2036.2003.01356.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/12492732/pubmed" id="12492732" target="_blank">12492732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24459647">
<a name="24459647"></a>Kim HR, Lee YS, Yim HJ, et al. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome. <i>Clin Mol Hepatol</i>. 2013;19(4):417-420. doi:10.3350/cmh.2013.19.4.417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/24459647/pubmed" id="24459647" target="_blank">24459647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31948983">
<a name="31948983"></a>Kulkarni AV, Kumar P, Rao NP, Reddy N. Terlipressin-induced ischaemic skin necrosis. <i>BMJ Case Rep</i>. 2020;13(1):e233089. doi:10.1136/bcr-2019-233089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/31948983/pubmed" id="31948983" target="_blank">31948983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23837143">
<a name="23837143"></a>Lee HJ, Oh MJ. A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. <i>Clin Mol Hepatol</i>. 2013;19(2):179-184. doi:10.3350/cmh.2013.19.2.179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/23837143/pubmed" id="23837143" target="_blank">23837143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15696791">
<a name="15696791"></a>Lee MY, Chu CS, Lee KT, et al. Terlipressin-related acute myocardial infarction: a case report and literature review. <i>Kaohsiung J Med Sci</i>. 2004;20(12):604-608. doi:10.1016/S1607-551X(09)70266-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/15696791/pubmed" id="15696791" target="_blank">15696791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31421059">
<a name="31421059"></a>Meng Q, Dang X, Li L, Liu Z, Li L, Wang H. Severe hyponatraemia with neurological manifestations in patients treated with terlipressin: Two case reports. <i>J Clin Pharm Ther</i>. 2019;44(6):981-984. doi:10.1111/jcpt.13031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/31421059/pubmed" id="31421059" target="_blank">31421059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26995205">
<a name="26995205"></a>Šíma M, Pokorný M, Paďour F, Slanař O. Terlipressin induced severe hyponatremia. <i>Prague Med Rep</i>. 2016;117(1):68-72. doi:10.14712/23362936.2016.7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/26995205/pubmed" id="26995205" target="_blank">26995205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23907969">
<a name="23907969"></a>Sundriyal D, Kumar N, Patnaik I, Kamble U. Terlipressin induced ischaemia of skin. <i>BMJ Case Rep</i>. 2013;2013:bcr2013010050. doi:10.1136/bcr-2013-010050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/23907969/pubmed" id="23907969" target="_blank">23907969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Terlivaz.1">
<a name="Terlivaz.1"></a>Terlivaz (terlipressin) [prescribing information]. Bridgewater, NJ: Mallinckrodt Hospitals Products Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23948983">
<a name="23948983"></a>Wang X, Wang Y, Gou W, Lu Q, Peng J, Lu S. Role of mesenchymal stem cells in bone regeneration and fracture repair: a review. <i>Int Orthop</i>. 2013;37(12):2491-2498. doi:10.1007/s00264-013-2059-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/23948983/pubmed" id="23948983" target="_blank">23948983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818227">
<a name="20818227"></a>Zimmer V, Lammert F. Terlipressin-induced skin necrosis and rhabdomyolysis. <i>Am J Med Sci</i>. 2010;340(6):506. doi:10.1097/MAJ.0b013e3181ee9873<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terlipressin-drug-information/abstract-text/20818227/pubmed" id="20818227" target="_blank">20818227</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139628 Version 32.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
